CME webinar: Heart Failure – Targeted Optimal Pharmacotherapy

Aug. 2024Education/Webinars

Please join us for a live, CME-accredited webinar on Wednesday, Oct. 30, from noon to 1 p.m. that will review targeted optimal pharmacotherapy in patients with heart failure.

At the end of this learning session, you will be able to:

  • Describe the pathophysiology and the physiological effects of key medication classes for heart failure.
  • Define the revisions in heart failure classification and guideline-directed medical therapy (GDMT) per the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure.
    • HFrEF (Quadruple therapy as the standard of care)
    • HFimpF
    • HFmrEF
    • HFpEF
  • Identify the risk and management of heart failure in people with diabetes.
  • Recognize the clinical benefits of GDMT for heart failure and the opportunities for improvement.
  • Describe the UPMC Health Plan GDMT heart failure initiative and clinical outcomes.

Presenters:

  • Nick DeGregorio, MD, MMM, FACP, AVP, Medicaid Services, UPMC Health Plan
  • Melinda Morgan, PharmD, Manager, Clinical Pharmacy, UPMC Health Plan

Register now. This webinar will be recorded.

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team. The University of Pittsburgh designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. The maximum number of hours awarded for this Continuing Pharmacy Education activity is 1.0 contact hour. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Provider is responsible for verifying CME eligibility.

Recent Announcements

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates

HelpScript service helps patients enroll in manufacturer copay assistance programs

End-to-end provider support helps ensure a smooth submission process
Oct. 2025Important Notices

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices